Provider of microbiome therapeutics for treating multiple diseases. The company is focusing on the development of targeted human microbiome therapeutics for the prevention and treatment of chronic inflammatory diseases, starting with allergic diseases. The company's flagship product is STMC-103H for treating atopic dermatitis, food allergy, and allergic asthma. Founded in 2016, headquartered in San Francisco, United States. The company has raised $42.0M in funding at the series c stage. The company operates in the Genomics sector with additional focus on Microbiome Therapeutics and Immunology. Its business model centers on Endocrine disorders. Founded in 2016, headquartered in San Francisco, United States. The company has raised $42.0M at the Series C stage. Backed by investors including SymBiosis, Khosla Ventures, Seventure Partners, Global Brain, TimeVentures and others.
Siolta Therapeutics
Series CProvider of microbiome therapeutics for treating multiple diseases. The company is focusing on the development of targeted human microbiome therapeutics for the prevention and treatment of chronic inflammatory diseases, starting with allergic diseases. The company's flagship product is STMC-103H for treating atopic dermatitis, food allergy, and allergic asthma. Founded in 2016, headquartered in San Francisco, United…
About
Business model
Metabolic Diseases > Drugs > Endocrine disorders,
Dermatology > Drugs > Diversified,
Immunology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Microbiomics
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.